miR-23a suppression accelerates functional decline in the rNLS8 mouse model of TDP-43 proteinopathy

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..

Skeletal muscle dysfunction may contribute to the progression and severity of amyotrophic lateral sclerosis (ALS). In the present study, we characterized the skeletal muscle pathophysiology in an inducible transgenic mouse model (rNLS8) that develops a TAR-DNA binding protein (TDP-43) proteinopathy and ALS-like neuropathology and disease progression; representative of >90% of all familial and sporadic ALS cases. As we previously observed elevated levels of miR-23a in skeletal muscle of patients with familial and sporadic ALS, we also investigated the effect of miR-23a suppression on skeletal muscle pathophysiology and disease severity in rNLS8 mice. Five weeks after disease onset TDP-43 protein accumulation was observed in tibialis anterior (TA), quadriceps (QUAD) and diaphragm muscle lysates and associated with skeletal muscle atrophy. In the TA muscle TDP-43 was detected in muscle fibres that appeared atrophied and angular in appearance and that also contained β-amyloid aggregates. These fibres were also positive for neural cell adhesion molecule (NCAM), but not embryonic myosin heavy chain (eMHC), indicating TDP-43/ β-amyloid localization in denervated muscle fibres. There was an upregulation of genes associated with myogenesis and NMJ degeneration and a decrease in the MURF1 atrophy-related protein in skeletal muscle. Suppression of miR-23a impaired rotarod performance and grip strength and accelerated body weight loss during early stages of disease progression. This was associated with increased AchRα mRNA expression and decreased protein levels of PGC-1α. The TDP-43 proteinopathy-induced impairment of whole body and skeletal muscle functional performance is associated with muscle wasting and elevated myogenic and NMJ stress markers. Suppressing miR-23a in the rNLS8 mouse model of ALS contributes to an early acceleration of disease progression as measured by decline in motor function.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:162

Enthalten in:

Neurobiology of disease - 162(2022) vom: 25. Jan., Seite 105559

Sprache:

Englisch

Beteiligte Personen:

Tsitkanou, Stavroula [VerfasserIn]
Della Gatta, Paul A [VerfasserIn]
Abbott, Gavin [VerfasserIn]
Wallace, Marita A [VerfasserIn]
Lindsay, Angus [VerfasserIn]
Gerlinger-Romero, Frederico [VerfasserIn]
Walker, Adam K [VerfasserIn]
Foletta, Victoria C [VerfasserIn]
Russell, Aaron P [VerfasserIn]

Links:

Volltext

Themen:

β-Amyloid
Amyotrophic lateral sclerosis
DNA-Binding Proteins
Journal Article
MiR-23a
MicroRNAs
Mirn23b microRNA, mouse
Motor neuron disease
Myogenic regulatory factors
RNLS8 mice
Research Support, Non-U.S. Gov't
Skeletal muscle
TDP-43
TDP-43 protein, mouse

Anmerkungen:

Date Completed 07.04.2022

Date Revised 12.07.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.nbd.2021.105559

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM33312555X